Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REMEDI: Antibiotics for Inflammation in Cardiac Surgery
NCT03939273Unknown
- Sponsor
- Radboud University Medical Center
- Start
- Mar 2022
- Primary completion
- Mar 2023
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, double-blind trial of ciprofloxacin, vancomycin, metronidazole and fluconazole in Systemic Inflammatory Response Syndrome (SIRS) (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Area Under the Curve of interleukin-6 plasma concentrations. Status: unknown.
02
Drugs
ciprofloxacinvancomycinmetronidazolefluconazole
03
Conditions
Systemic Inflammatory Response Syndrome (SIRS)
Beyond the preview
Go deeper on NCT03939273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03939273.